Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTRB1 | P17538 | 2/20 | 0.49 |
| ▸ | ELANE | P08246 | 2/20 | 0.49 |
| ▸ | IGLV6-57 | P01721 | 2/20 | 0.34 |
| ▸ | NAMPT | P43490 | 4/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.32 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | NAPEPLD | Q6IQ20 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6640507 | 0.97 | CTRB1 (0.50) | CTRB1ELANEIGLV6-57NAMPTCYP3A4 | |
| SCHEMBL6712777 | 0.93 | CTRB1 (0.50) | CTRB1ELANENAMPTCYP3A4PDE7B | |
| SCHEMBL6637568 | 0.92 | CTRB1 (0.49) | CTRB1ELANENAMPTCYP3A4PDE7B | |
| SCHEMBL6637693 | 0.92 | CTRB1 (0.49) | CTRB1ELANE | |
| SCHEMBL6636735 | 0.91 | CTRB1 (0.49) | CTRB1ELANE | |
| SCHEMBL6637147 | 0.90 | CTRB1 (0.51) | CTRB1ELANENAMPTCYP3A4PDE7B | |
| SCHEMBL6637178 | 0.89 | CTRB1 (0.51) | CTRB1ELANE | |
| SCHEMBL6635312 | 0.87 | CTRB1 (0.51) | CTRB1ELANEPDE7B | |
| SCHEMBL6642417 | 0.86 | CTRB1 (0.51) | CTRB1ELANEPDE7B | |
| SCHEMBL6634354 | 0.86 | CTRB1 (0.53) | CTRB1ELANEIGLV6-57NAMPTCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040116420-A1 | Remedial agent for viral infectious disease | ASAHI KASEI PHARMA CORPORATION (JP) | 2004-06-17 | — | — | US | disclosed |
| EP-1403269-A1 | REMEDIAL AGENT FOR VIRAL INFECTIOUS DISEASE | Asahi Kasei Pharma Corporation (JP) | 2004-03-31 | — | — | EP | disclosed |